Product image of Lenzetto (Estradiol Hemihydrate) supplied by GNH India

Lenzetto

Active Ingredient:
Estradiol Hemihydrate
Origin:
EU

Lenzetto (Estradiol Hemihydrate)

Estradiol, the active ingredient in Lenzetto, is an estrogen presented as a transdermal patch for transdermal use. It provides hormone replacement therapy to alleviate menopausal vasomotor symptoms and to prevent postmenopausal osteoporosis in women.

GNH India supplies Lenzetto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Gedeon Richter Plc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Lenzetto delivers estradiol to target estrogen‑dependent pathways, addressing several menopause‑related conditions.
  • Menopausal vasomotor symptoms: reduces hot flashes and night sweats in postmenopausal women.
  • Postmenopausal osteoporosis: helps maintain bone mineral density and lowers fracture risk.
  • Hypoestrogenism due to ovarian failure or hypogonadism: restores estrogen levels in women with low endogenous production.

How It Works

  • Estradiol acts as an agonist at estrogen receptors (ERα and ERβ) in target tissues. Binding activates the receptors, leading to modulation of gene transcription that regulates reproductive, skeletal, and vascular functions, thereby restoring estrogenic activity in hypoestrogenic states.

Side Effects

Transdermal estradiol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Skin irritation at the patch site: redness, itching or rash.
  • Headache: mild to moderate intensity.
  • Breast tenderness: discomfort or swelling.
  • Nausea: occasional upset stomach.
  • Mood changes: irritability or mild depression.
  • Bloating: abdominal fullness.

Serious or Rare Side Effects

  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Stroke or transient ischemic attack.
  • Myocardial infarction: heart attack risk.
  • Gallbladder disease: cholecystitis or gallstones.
  • Hepatic dysfunction: abnormal liver enzymes.
  • Endometrial hyperplasia or cancer: especially if unopposed by progestogen.

Precautions & Warnings

  • Before prescribing Lenzetto, clinicians should evaluate several safety considerations.
  • Assess cardiovascular risk: review history of thromboembolism, stroke or myocardial infarction.
  • Screen for estrogen‑sensitive cancers: avoid in active breast or endometrial cancer.
  • Monitor liver function: adjust use in patients with hepatic impairment.
  • Consider bone health: incorporate into comprehensive osteoporosis management.
  • Avoid use during pregnancy: contraindicated in pregnant women.
  • Store at room temperature below 25°C: keep in the original pouch, protect from moisture and direct sunlight.

Avoid Interactions

Estradiol can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

  • Combined estrogen‑containing oral contraceptives: increased risk of thromboembolic events.
  • Anticoagulants (e.g., warfarin): potential enhancement of anticoagulant effect.
  • Selective estrogen receptor modulators (e.g., tamoxifen): antagonistic pharmacodynamic interaction.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (rifampin, carbamazepine): may reduce estradiol plasma levels.
  • CYP3A4 inhibitors (ketoconazole, erythromycin): may increase estradiol exposure.
  • Thyroid hormone replacement therapy: may require dose adjustment of levothyroxine.

Frequently Asked Questions

Lenzetto is a transdermal estradiol patch indicated for relief of moderate to severe vasomotor symptoms of menopause, prevention of osteoporosis in postmenopausal women, and treatment of hypoestrogenism caused by ovarian failure or hypogonadism.

Estradiol in Lenzetto binds to estrogen receptors (ERα and ERβ) in target tissues, activating them and modulating transcription of estrogen‑responsive genes. This restores estrogenic activity, improving vasomotor control, bone metabolism, and other estrogen‑dependent functions.

The specific dose and patch change interval are determined by the prescribing clinician based on the individual’s therapeutic needs, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions exactly.

Lenzetto is contraindicated in pregnancy because exogenous estrogen can harm the fetus. Safety during breastfeeding has not been established; therefore, it should be avoided unless the benefits clearly outweigh potential risks and a healthcare professional advises otherwise.

To order Lenzetto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenzetto delivers estradiol through the skin, providing more stable serum levels and avoiding first‑pass hepatic metabolism compared with oral estrogen tablets. This route may reduce certain hepatic side effects while offering similar efficacy for menopausal symptom control and bone protection.

Store Lenzetto at room temperature below 25 °C. Keep the patches in their original pouch, protect them from moisture, direct sunlight and extreme temperatures. Do not expose the product to excessive heat or humidity to maintain potency.

The patch is applied to clean, dry, hair‑free skin on the lower abdomen, buttock, or upper arm. Press firmly for several seconds, then replace the patch according to the prescriber’s schedule, typically every 3–4 days, rotating sites to avoid skin irritation.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, stroke, myocardial infarction, and, in rare cases, endometrial hyperplasia or cancer if estrogen is not balanced with progestogen in women with a uterus.

Lenzetto should not be used by women with active breast or endometrial cancer, a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or by anyone who is pregnant. It is also contraindicated in individuals with known hypersensitivity to estradiol or patch components.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Estradiol Hemihydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT